BTIG Research Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

Liquidia (NASDAQ:LQDA) had its target price hoisted by investment analysts at BTIG Research from $49.00 to $50.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 44.84% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. HC Wainwright increased their price objective on Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday. Jefferies Financial Group upped their price target on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.56.

Liquidia Price Performance

Liquidia stock opened at $34.52 on Thursday. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -23.97, a PEG ratio of 0.60 and a beta of 0.52. Liquidia has a 52-week low of $11.26 and a 52-week high of $46.67. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The stock’s 50 day moving average price is $37.07 and its two-hundred day moving average price is $30.84.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $92.02 million during the quarter. Liquidia’s revenue for the quarter was up 3072.4% compared to the same quarter last year. On average, equities analysts predict that Liquidia will post -1.51 earnings per share for the current year.

Insider Activity

In related news, insider Scott Moomaw sold 20,533 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $768,550.19. Following the completion of the transaction, the insider owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. This trade represents a 11.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Kaseta sold 36,932 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,382,364.76. Following the transaction, the chief financial officer owned 350,919 shares of the company’s stock, valued at $13,134,898.17. This trade represents a 9.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 212,534 shares of company stock worth $7,964,719. 26.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP purchased a new position in Liquidia in the fourth quarter worth approximately $3,148,000. Invesco Ltd. raised its holdings in shares of Liquidia by 428.3% in the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after purchasing an additional 341,009 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Liquidia during the 4th quarter worth $1,214,000. nVerses Capital LLC acquired a new position in shares of Liquidia during the fourth quarter worth $335,000. Finally, Occudo Quantitative Strategies LP purchased a new position in Liquidia in the fourth quarter valued at $3,107,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported robust YUTREPIA uptake, $148.3M net product sales for 2025, $90.1M in Q4, a second consecutive profitable quarter and $190.7M cash — a clear commercialization win that supports longer-term revenue visibility. Read More.
• Positive Sentiment: HC Wainwright materially raised multi-year earnings forecasts (FY2026–FY2029) and lifted near-term Q4 estimates — analyst bullishness can underpin upside as sell-side models shift higher. Read More.
• Neutral Sentiment: Transcript and call highlights show management emphasizing rapid prescriber adoption, plans to expand the sales force and fund development from operations — useful context for investors but not an immediate catalyst. Read More.
• Neutral Sentiment: Market commentary and valuation pieces weigh whether the post-launch run-up leaves room for further gains; this shapes investor positioning (buyers vs. profit-takers). Read More.
• Negative Sentiment: Shares gapped down in pre-market trading after the quarter amid perceptions the $0.15 EPS print failed to meet some consensus targets; that short-term disappointment drove selling pressure. Read More.
• Negative Sentiment: Despite strong sales, reporting differences vs. certain consensus figures (and a mixed presentation of GAAP vs. non‑GAAP metrics) created confusion and volatility around the print. Read More.
• Negative Sentiment: Notable insider and institutional selling (Quiver/SEC filings) and a reported $5.1M manager sale add near-term supply pressure and may weigh on sentiment until clearer follow-through from sales growth. Read More. Read More.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).